Key Insights

Highlights

Success Rate

50% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

50.0%

-36.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

3Total

P 1 (2)

P 2 (1)

Trial Status

Terminated1

Completed1

Recruiting1

Trial Success Rate

50.0%

Benchmark: 86.5%

Based on 1 completed trials

Clinical Trials (3)

Showing 3 of 3 trials

NCT06503276Phase 2RecruitingPrimary

The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy

NCT01523223Phase 1Completed

Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies

NCT00288067Phase 1Terminated

Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Showing all 3 trials

Extranodal Marginal Zone B-cell Lymphoma